Inventiva (NYSE:IVA) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.
Profitability
This table compares Inventiva and Cullinan Oncology's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Inventiva | N/A | N/A | N/A |
Cullinan Oncology | N/A | N/A | N/A |
Earnings & Valuation
This table compares Inventiva and Cullinan Oncology's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Inventiva | N/A | N/A | N/A | N/A | N/A |
Cullinan Oncology | N/A | N/A | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent ratings for Inventiva and Cullinan Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Inventiva | 1 | 0 | 4 | 0 | 2.60 |
Cullinan Oncology | 0 | 1 | 3 | 0 | 2.75 |
Inventiva currently has a consensus price target of $27.3333, suggesting a potential upside of 89.29%. Cullinan Oncology has a consensus price target of $48.25, suggesting a potential upside of 49.38%. Given Inventiva's higher probable upside, research analysts plainly believe Inventiva is more favorable than Cullinan Oncology.
Summary
Inventiva beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.